Headlines about Wave Life Sciences (NASDAQ:WVE) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Wave Life Sciences earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.4772812156309 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- Equities Analysts Set Expectations for Wave Life Sciences Ltd’s Q1 2019 Earnings (WVE) (americanbankingnews.com)
- Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update (finance.yahoo.com)
- Post-Traumatic Stress Disorder: A Review of Therapeutic Role of Meditation Interventions (lankaweb.com)
- Wave Life Sciences (WVE) PT Raised to $60.00 (americanbankingnews.com)
Wave Life Sciences (NASDAQ:WVE) traded down $1.08 during mid-day trading on Wednesday, reaching $42.22. The company had a trading volume of 86,517 shares, compared to its average volume of 163,873. The firm has a market capitalization of $1,256.85, a P/E ratio of -11.00 and a beta of 0.14. Wave Life Sciences has a fifty-two week low of $15.15 and a fifty-two week high of $55.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.50 and a current ratio of 11.50.
In other news, insider Chris Francis sold 21,639 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $55.40, for a total transaction of $1,198,800.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Michael A. Panzara sold 511 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $52.10, for a total value of $26,623.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,466 shares of company stock valued at $1,321,808. 53.00% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Wave Life Sciences (NASDAQ:WVE) Receiving Somewhat Favorable News Coverage, Study Shows” was first published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/14/wave-life-sciences-wve-given-daily-news-impact-score-of-0-07/1972928.html.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.